https://www.diabesityrounds.com/a/lower-gdm-diagnostic-thresholds-doubled-diagnoses-without-better-short-term-outcDiabesity Roundsen2026-10-31T20:17:14.826ZLower GDM diagnostic thresholds doubled diagnoses without better short-term outcomeshttps://www.diabesityrounds.com/a/oral-orforglipron-reduced-bodyweight-more-than-placebo-at-72-weeks-in-japanese-aDiabesity Roundsen2026-10-31T20:02:33.017ZOral orforglipron reduced bodyweight more than placebo at 72 weeks in Japanese adultshttps://www.diabesityrounds.com/a/litmus-somasignal-panel-most-accurate-for-at-risk-mash-and-advanced-fibrosisDiabesity Roundsen2026-10-30T20:32:46.373ZLITMUS: SomaSignal panel most accurate for at-risk MASH and advanced fibrosishttps://www.diabesityrounds.com/a/statstrip-gen-2-0-hospital-glucose-meter-recall-results-may-go-to-wrong-patientDiabesity Roundsen2026-10-30T20:17:20.680ZStatStrip Gen 2.0 hospital glucose meter recall: results may go to wrong patienthttps://www.diabesityrounds.com/a/cdsco-expert-committee-phase-iii-trial-of-degludec-aspart-mix-recommendedDiabesity Roundsen2026-10-30T20:02:26.360ZCDSCO expert committee: Phase III trial of degludec/aspart mix recommended